Clinical trials
Urinary Tract Infections trials in Denmark
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 4 |
| Unknown status | 4 |
| Not yet recruiting | 3 |
| Withdrawn | 2 |
| No longer available | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Copenhagen | 4 |
| Rigshospitalet, Denmark | 3 |
| University of Southern Denmark | 3 |
| Odense University Hospital | 2 |
| Research Unit Of General Practice, Copenhagen | 2 |
| Coloplast A/S | 1 |
| Herlev and Gentofte Hospital | 1 |
| Hvidovre University Hospital | 1 |
| Impatients N.V. trading as myTomorrows | 1 |
| Jacob Bodilsen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Tract Infections | 25 |
| Infections | 3 |
| Bacterial Infections | 2 |
| Disease | 2 |
| Emergencies | 2 |
| Sepsis | 2 |
| Bacteremia | 1 |
| Bacteriuria | 1 |
| Cellulitis | 1 |
| Community-Acquired Pneumonia | 1 |
Trials
Showing 51 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.